Terms: = Breast cancer AND BCL11A, BCL11A-L, 53335, ENSG00000119866, FLJ34997, CTIP1, BCL11A-S, BCL11A-XL, KIAA1809, Q9H165, EVI9, FLJ10173 AND Prognosis
5 results:
1. Exploration of Key Immune-Related Transcriptomes Associated with Doxorubicin-Induced Cardiotoxicity in Patients with breast cancer.
Xiong D; Yang J; Li D; Wang J
Cardiovasc Toxicol; 2023 Oct; 23(9-10):329-348. PubMed ID: 37684436
[TBL] [Abstract] [Full Text] [Related]
2. Integrated bioinformatics and statistical approaches to explore molecular biomarkers for breast cancer diagnosis, prognosis and therapies.
Alam MS; Sultana A; Reza MS; Amanullah M; Kabir SR; Mollah MNH
PLoS One; 2022; 17(5):e0268967. PubMed ID: 35617355
[TBL] [Abstract] [Full Text] [Related]
3. Network Analysis Identifies Regulators of Basal-Like breast cancer Reprogramming and Endocrine Therapy Vulnerability.
Choi SR; Hwang CY; Lee J; Cho KH
Cancer Res; 2022 Jan; 82(2):320-333. PubMed ID: 34845001
[TBL] [Abstract] [Full Text] [Related]
4. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting bcl11a and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
[TBL] [Abstract] [Full Text] [Related]
5. Exploring specific prognostic biomarkers in triple-negative breast cancer.
Bao C; Lu Y; Chen J; Chen D; Lou W; Ding B; Xu L; Fan W
Cell Death Dis; 2019 Oct; 10(11):807. PubMed ID: 31649243
[TBL] [Abstract] [Full Text] [Related]
